Cellulitis News and Research

Latest Cellulitis News and Research

Amgen and Merck expand collaboration for Talimogene laherparepvec-KEYTRUDA combination study

Amgen and Merck, known as MSD outside the U.S. and Canada, today announced an expanded collaboration to evaluate the efficacy and safety of talimogene laherparepvec, Amgen's investigational oncolytic immunotherapy, in combination with KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, in a Phase 1, open-label trial of patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN).

1 Jun 2015

Ebola outbreak emphasizes the importance of monitoring disease burden in developing countries

A study recently published in the Journal of the American Academy of Dermatology shows that for Ebola, measles, syphilis and many other conditions with skin manifestations the mortality rates are hundreds of times higher in developing countries than they are in developed countries.

16 Oct 2014

FDA grants QIDP and Fast Track designation to Nabriva's lefamulin for treatment of CABP, ABSSSI

Nabriva Therapeutics AG, a biotechnology company focused on developing pleuromutilins, a new class of antibiotics for the treatment of serious infections caused by resistant Gram-positive and Gram-negative pathogens, announced today that the United States Food and Drug Administration has granted Qualified Infectious Disease Product (QIDP) as well as Fast Track status designation to Nabriva's lead product lefamulin, for the treatment of community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI).

8 Oct 2014

Cubist Pharmaceuticals' SIVEXTRO receives FDA approval for treatment of ABSSSI

Cubist Pharmaceuticals, Inc. announced today the U.S. Food and Drug Administration approved SIVEXTRO (tedizolid phosphate) for the treatment of adult acute bacterial skin and skin structure infections (ABSSSI).

21 Jun 2014

Cubist Pharmaceuticals publishes positive results from Phase 3 clinical trial of SIVEXTRO

Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced that The Lancet Infectious Diseases published online the positive results from ESTABLISH-2, a pivotal Phase 3 clinical trial of the investigational antibiotic SIVEXTRO™ (tedizolid phosphate), which is being developed for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and complicated skin and soft tissue infections (cSSTI).

9 Jun 2014

New antibiotic proves effective in treating serious bacterial skin and skin-structure infections

A study published in today's New England Journal of Medicine reports that the antibiotic dalbavancin is as effective as vancomycin, the current standard-of-care antibiotic used to treat serious bacterial skin and skin-structure infections.

5 Jun 2014

FDA accepts Cubist Pharmaceuticals' tedizolid phosphate NDA with Priority Review

Cubist Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has accepted the Company's New Drug Application for its investigational antibiotic tedizolid phosphate (TR-701) with Priority Review. The FDA has assigned a Prescription Drug User Fee Act action date of June 20, 2014. Cubist is seeking FDA approval of tedizolid for the treatment of acute bacterial skin and skin structure infections.

30 Dec 2013

Pharmacyclics presents ibrutinib trial data for B-cell malignancies at ASH meeting

Pharmacyclics, Inc. today announced results of 40 clinical, non-clinical and pre-clinical presentations on ibrutinib (IMBRUVICA™) at the 55TH Annual meeting of the American Society of Hematology (ASH) held in New Orleans, Dec 7 - 10, 2013.

11 Dec 2013

‘Flesh-eating’ disease treatments: an interview with Dr. John Crew, Seton Medical Center

Untreated, the mortality probably exceeds 70%. Flesh eating is a description of Toxic Inflammatory Cellulitis which usually starts by bacterial subcutaneous infection followed by freezing in phase II healing which is inflammatory.

9 Dec 2013

NeutroPhase irrigation therapy and NPWT help treat severe flesh eating and wound infections

NovaBay Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing topical non-antibiotic antimicrobial products, today announced the publication of a scientific paper by Dr. John R. Crew of Seton Medical Center, Daly City, California, describing the first use of adjunctive NeutroPhase irrigation therapy in conjunction with Negative Pressure Wound Therapy to successfully manage the severely-infected wound in the arm of a patient with life-threatening 'flesh-eating' disease.

20 Nov 2013

Amgen presents data from several romosozumab and Prolia at ASBMR 2013 Annual Meeting

Amgen today announced that it will present data from several romosozumab and Prolia® (denosumab) studies at the American Society for Bone and Mineral Research (ASBMR) 2013 Annual Meeting in Baltimore from Oct. 4-7, 2013.

5 Oct 2013

AMGEN announces additional results from talimogene laherparepvec Phase 3 trial

AMGEN today announced additional results from a pivotal Phase 3 trial evaluating talimogene laherparepvec in patients with unresected stage IIIB, IIIC or IV melanoma compared to granulocyte-macrophage colony-stimulating factor (GM-CSF).

30 Sep 2013

Incidence of septicemia increasing among service members, study finds

The annual incidence rates of primary diagnosed septicemia among active component service members increased nearly 580 percent from 2004 to 2012, according to a new study.

6 Sep 2013

Innovative microsurgery technique helps prevent lymphedema in patients with breast cancer

A team of surgeons and members of the breast cancer program of the Herbert Irving Comprehensive Cancer Center at NewYork-Presbyterian Hospital/Columbia University Medical Center is conducting a two-year pilot study of an innovative microsurgery technique coupled with imaging technology to not only prevent lymphedema but also potentially detect and treat it early.

24 Jul 2013

Symptoms, first-aid treatments and prevention tips for insect bites

Whether they are invading your picnic, hitching a ride on your skin or just buzzing around your head, bugs are an annoying and unavoidable part of summer. Still, there are times when bugs are just a nuisance and times when they can cause serious illness or injury.

24 Jul 2013

Orlando Health's clinicians provide hospital-level care in patient's home

Instead of admitting patients to medical units at the hospital, clinicians at Orlando Regional Medical Center are providing health care to patients in the comfort of their homes. The new twist on modern medicine is being piloted in a project to provide hospital-level care in a patient's home through home visits, videoconferencing (virtual visit) and telemonitoring (remote vital signs monitoring).

28 Jun 2013

Amgen reports encouraging results from talimogene laherparepvec phase 3 study in patients with metastatic melanoma

Amgen today announced detailed results from a pivotal Phase 3 trial evaluating talimogene laherparepvec in patients with unresected stage IIIB, IIIC or IV melanoma compared to granulocyte-macrophage colony-stimulating factor (GM-CSF).

3 Jun 2013

Positive results from Affinium Pharmaceuticals' Phase 2a clinical trial of AFN-1252 in ABSSSI

Affinium Pharmaceuticals announced today that its Phase 2a clinical trial evaluating oral AFN-1252 in acute bacterial skin & skin structure infections demonstrated excellent efficacy and safety data, marking a significant proof-of-concept milestone for Affinium's first-in-class, novel antibiotic targeted against bacterial fatty acid biosynthesis inhibition (FabI inhibitors).

21 Mar 2013

Checklist diverts inebriated from emergency department

A checklist for use by ambulance crews helps paramedics decide which drunk patients need emergency medical care and which can be diverted to a detoxification facility, say researchers.

22 Nov 2012

Radical sternectomy could be less risky than conservative

Researchers say that radical sternectomy encompassing the costal cartilages leads to a significantly lower rate of complications and reoperation than conservative sternectomy.

8 Nov 2012

Cellulitis News and Research

Latest Cellulitis News and Research

Amgen and Merck expand collaboration for Talimogene laherparepvec-KEYTRUDA combination study

Ebola outbreak emphasizes the importance of monitoring disease burden in developing countries

FDA grants QIDP and Fast Track designation to Nabriva's lefamulin for treatment of CABP, ABSSSI

Cubist Pharmaceuticals' SIVEXTRO receives FDA approval for treatment of ABSSSI

Cubist Pharmaceuticals publishes positive results from Phase 3 clinical trial of SIVEXTRO

New antibiotic proves effective in treating serious bacterial skin and skin-structure infections

FDA accepts Cubist Pharmaceuticals' tedizolid phosphate NDA with Priority Review

Pharmacyclics presents ibrutinib trial data for B-cell malignancies at ASH meeting

‘Flesh-eating’ disease treatments: an interview with Dr. John Crew, Seton Medical Center

NeutroPhase irrigation therapy and NPWT help treat severe flesh eating and wound infections

Amgen presents data from several romosozumab and Prolia at ASBMR 2013 Annual Meeting

AMGEN announces additional results from talimogene laherparepvec Phase 3 trial

Incidence of septicemia increasing among service members, study finds

Innovative microsurgery technique helps prevent lymphedema in patients with breast cancer

Symptoms, first-aid treatments and prevention tips for insect bites

Orlando Health's clinicians provide hospital-level care in patient's home

Amgen reports encouraging results from talimogene laherparepvec phase 3 study in patients with metastatic melanoma

Positive results from Affinium Pharmaceuticals' Phase 2a clinical trial of AFN-1252 in ABSSSI

Checklist diverts inebriated from emergency department

Radical sternectomy could be less risky than conservative

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Cellulitis News and Research

Latest Cellulitis News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in